Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

VANCOUVER, July 3 /PRNewswire/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the companies have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011. Under the amended agreement, OncoGenex is solely responsible for all future development activities, costs and partnering decisions related to OGX-011. Isis will no longer be responsible for funding 35% of development costs, will receive single digit royalties on future revenues of OGX-011, and will receive a portion of license fees and milestone payments received by OncoGenex from any future partner. There were no upfront payments associated with this amended agreement.

"This amendment allows us to increase our economic interest in OGX-011 as we advance the development of OGX-011 while also increasing our flexibility to further develop this product candidate," said Scott Cormack, President and CEO of OncoGenex. "In addition, we believe this new arrangement facilitates future partnering discussions since potential development and commercialization partners need only deal with one party."

"This amended agreement with OncoGenex is consistent with our strategy to remain focused on discovering and developing drugs and licensing prior to large Phase 3 trials. This has enabled us to continue to benefit from the successes of antisense drugs through a growing annuity of licensing fees, milestones and royalty payments with many focused partners," said B. Lynne Parshall, COO and CFO of Isis. "We believe that clinical results to date have established OGX-011 as one of many promising antisense drugs and OncoGenex is now ideally situated to lead the final stages of development of OGX-011 whi
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... PDS, a leader in providin...community, announces Pajama Pathology®, evolut...g the same ‘gold standard’ software us...the world, but on a ‘cost per slide’ b...NJ (PRWEB) November 30, 2009 -- PDS has announced ...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , LONDON, November 30 /PRNew...ics company, was named Europe,s fastest growing,Bi...company in the Deloitte,2009 Technology Fast 500 f... This annual ranking is based on a companies, fi...eved a rate of 8,318% over this period. This,achie...
(Date:11/29/2009)... This release is available in German . , T...eas in modern physics. The most famous example is ... and neutrons. Now Prof. Bella Lake from Helmholtz...m of scientists report for the first time an exper...nomenon observed in a condensed matter system. , ...
Breaking Biology Technology:Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4Spinons -- confined like quarks 2
... a provider of long-term care services in New Eng...Wendy LaBate has been promoted to Senior Vice Pres...r new position, LaBate will be responsible for pro...Genesis, Regional Vice Presidents of Operations an... center operations, improve efficiencies and promo...
...q: CEPH ) announced today that Sarma P. Duddu, P...ce President of Drug Delivery Technologies of CIMA... aspects of the Cephalon drug delivery business at...ocated in suburban Minnesota. , , (Photo: htt... ) , , In his new role, Dr. Duddu will be a membe...
... Institute Pharma,(TI Pharma) has formed a consort...y Medical Centre and Nobilon, a subsidiary of Sch...ine against the Chikungunya virus. This,vaccine ai... Viral disease epidemics have increased in inc...these diseases is caused by the Chikungunya virus,...
Other Biology Technology:Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 3Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 4Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership 2
(Date:11/30/2009)...ratures continue to rise scientists are presented ...ecies respond and adapt. In a paper published in ...odriguez-Trelles and Dr Miguel Rodriguez assess th... of approximately 0.6˚C has already affected ...ng ecologists and evolutionary biologists is to pr...
(Date:11/30/2009)...report published in the December 2009 print issue ...lar type of control over their fertility that wome...sts have found how and where androgenic hormones w...on and male fertility. This opens a promising aven...discovery also offers hope to those who cannot hav...
(Date:11/26/2009)...r impressive antlers, red deer have been caught in... antlers are much more than decorative. They are l...ing. John Currey, from The University of York, UK,...f bone for over half a century and has become fasc...ugh a long-standing collaboration with Tomas Lande...
Breaking Biology News(10 mins):How can scientists measure evolutionary responses to climate change? 2Tough yet stiff deer antler is materials scientist's dream 2Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 1Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 2Hologic to Present at the 29th Annual Canaccord Adams Global Growth Conference 51475 1Hush little baby Linking genes brain and behavior in children 9237 1Hush little baby Linking genes brain and behavior in children 9237 2
... New knowledge points to the fact that a genetical... skin barrier, plays a decisive role in the origin...school-children scientists of the Helmholtz Zentru...d that about 8% of the German population carry var...k to develop atopic dermatitis more than threefold...
... Measures for better air , Now that Olympia is ap...educe the air pollution in the large cities with d... Beijing is massively limited: the government has ... Private cars are only allowed to drive on even or...number. Furthermore, legal regulations have been i...
... PHILADELPHIA Based on a pilot study in children ...es of Health (NIH) believe that immunotherapy coul...this cancer. , The researchers tested a novel de...to potentially strengthen the immune system post c...ust 1 issue of Clinical Cancer Research , a journ...
Other Biology News:When our protective armor shows weakness 2GKSS membranes reduce air pollution in Beijing 2Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
...ost comprehensive, cost-effective solution to your...ated unprecedented quality into both our products ...ection chemistries and antibodies that have been o...s our competitively priced accessories that can be...
Mouse Anti-Yellow Fever Virus Monoclonal Antibody, Unconjugated, Clone 3576 from Abcam
Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Gel Loading Dye (Bromophenol Blue/Glycerol) from Mo Bio Laboratories, Inc.
Biology Products: